1. Home
  2. FUSB vs ONCY Comparison

FUSB vs ONCY Comparison

Compare FUSB & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First US Bancshares Inc.

FUSB

First US Bancshares Inc.

HOLD

Current Price

$15.03

Market Cap

90.8M

Sector

Finance

ML Signal

HOLD

Logo Oncolytics Biotech Inc.

ONCY

Oncolytics Biotech Inc.

HOLD

Current Price

$0.89

Market Cap

94.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FUSB
ONCY
Founded
1952
1998
Country
United States
Canada
Employees
N/A
N/A
Industry
Major Banks
Pharmaceuticals and Biotechnology
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
90.8M
94.0M
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
FUSB
ONCY
Price
$15.03
$0.89
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$6.00
AVG Volume (30 Days)
9.0K
1.9M
Earning Date
01-28-2026
03-06-2026
Dividend Yield
1.80%
N/A
EPS Growth
N/A
N/A
EPS
1.00
N/A
Revenue
$37,006,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$15.59
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.30
$0.33
52 Week High
$15.99
$1.51

Technical Indicators

Market Signals
Indicator
FUSB
ONCY
Relative Strength Index (RSI) N/A 36.51
Support Level N/A $0.81
Resistance Level N/A $1.06
Average True Range (ATR) 0.00 0.10
MACD 0.00 -0.03
Stochastic Oscillator 0.00 2.88

Price Performance

Historical Comparison
FUSB
ONCY

About FUSB First US Bancshares Inc.

First US Bancshares Inc is a bank holding company. The Bank conducts general commercial banking business and offers banking services such as demand, savings, individual retirement account and time deposits, personal and commercial loans, safe deposit box services, and remote deposit capture. The Bank provides a range of commercial banking services to small and medium-sized businesses, property managers, business executives, professionals, and other individuals.

About ONCY Oncolytics Biotech Inc.

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.

Share on Social Networks: